Wells Fargo analyst Elyse Greenspan maintains Ryan Specialty Holdings (NYSE:RYAN) with a Equal-Weight and lowers the price target from $44 to $41.
CEL-SCI Presents Head & Neck Cancer Data At IDDST Annual Congress In Budapest: Risk Of Death Cut In Half For Patients Treated With Multikine In The Target Population
Multikine significantly increases overall survival in patients with low levels of tumor cell PD-L1 expression in contrast to approved checkpoint inhibitors73% survival for Multikine vs 45% in the control arm at 5
